Sometime in mid-2015, a young cancer patient in New York City was driven to desperation. The family had built a treatment war chest of a few million dollars but the drugs weren’t working. None at all. Not even Keytruda, the expensive breakthrough drug from Merck & Co. which was approved around that time. Through academic connections, the family learnt about Mitra Biotech’s cancer diagnostics technology which the company offered on a compassionate ground. The diagnostic test threw up, to everyone’s surprise, a drug option which was low on everyone’s priority, and also, price.

The $20 chemotherapy drug Topotecan did wonders; the 6 cm tumour vanished.

Two years later, Mallikarjun Sundaram and Pradip Majumder, co-founders of Mitra, cite that case as one of the many ‘good’ surprises in their records as they embark on building regulatory-grade real-world evidence of how their tech works.

In a massive 1600 patient trial, 800 each in India and the United States, Mitra is out to capture in a year the true economic and medical value of its technology. In a complex disease like cancer, drugs are often given in combination. Yet the success rate is abysmal, as low as 20%. The hit-and-miss treatment is avoided in some cancers where there are genetic markers. The patients are then tested for the marker and given the right drugs. However, a new class of drugs called immunotherapy has entered the market—and more than 600 are in development across the world—with an annual cost upwards of $100,000. The hype around most of these encourages rampant off-label use as a last-ditch effort to stall cancer. It’s debatable how much of it is medical advancement and how much leads down a slippery slope because there’s no reliable way of predicting who will benefit and who will not.

Mitra thinks its platform CANScript can. To a great extent, and for the time being, in many types of cancers. So now that its tech can match the patient and the cancer drug up to 90% of the time, the biotech is switching growth tracks.

Deep science & tech companies like Mitra and Strand are capital efficient. Unlike other heavily funded startups which have to give a quick turnaround to their VCs. They may become unicorns, but they are never profitable

Vijay Chandru, Chairman, Strand

Ten years ago, Majumder and Sundaram came from Massachusetts Institute of Technology to Bengaluru to build technology that can be applied globally. Getting clinical samples was easier in India. Now they’ve turned the spotlight back to the Boston area, even flipping the corporate structure. All in preparation for a possible Nasdaq listing. Mitra Biotech is now a brand owned by the US-based parent Mitra RxDx Inc. and Mitra RxDx Pvt Ltd is the fully-owned India subsidiary.

When the US-India patient study completes early 2019, Mitra might be able to do what many modern cancer diagnostics providers have only been aspiring for—reimbursement from payers.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at support@the-ken.com with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at info@the-ken.com or follow us on Twitter.